Neurocrine Biosciences, Inc. (LON: 0K6R)
London
· Delayed Price · Currency is GBP · Price in USD
152.89
-0.89 (-0.58%)
Jan 31, 2025, 7:14 PM BST
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $622.10M USD in the quarter ending September 30, 2024, with 24.72% growth. This brings the company's revenue in the last twelve months to $2.24B, up 25.72% year-over-year. In the year 2023, Neurocrine Biosciences had annual revenue of $1.89B with 26.76% growth.
Revenue (ttm)
$2.24B
Revenue Growth
+25.72%
P/S Ratio
n/a
Revenue / Employee
$1.60M
Employees
1,400
Market Cap
12.37B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Neurocrine Biosciences News
- 2 days ago - Neurocrine Biosciences Inc (NBIX) Announces Q4 and Year-End 2024 Financial Results Conference Call - GuruFocus
- 2 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results - PRNewsWire
- 5 days ago - Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights - Benzinga
- 5 days ago - Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults - PRNewsWire
- 5 days ago - Neurocrine Biosciences Secures Global Rights to Develop Osavampator - GuruFocus
- 5 days ago - Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) - PRNewsWire
- 9 days ago - Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device - PRNewsWire
- 11 days ago - Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism - PRNewsWire